A randomized, placebo-controlled trial of deoxynucleotide and pegylated interferon α-2a in treatment of chronic hepatitis B(CHB﹚ with abnormal liver function / 中国现代医生

ABSTRACT

Objective To evaluate the clinical efficacy of deoxynucleotide combined with pegylated interferon α-2a in the treatment of chronic hepatitis B (CHB﹚ with liver injury. Methods All 92 cases of CHB with liver injury patients were selected in our clinical study. All patients were randomly divided into treatment group(n=46, treated with PEG-IFNα-2a and deoxynucleotide acid injection, 200 mg/d, intravenous drip﹚and control group (n=46, treated with PEG-IFNα-2a﹚.Then assessment of CHB serum markers and liver function after 48 weeks continuous treatment. Results There were significant differences between the two groups in the HBV-DNA negative rate (60.7% v s 39.2%﹚, the HBeAg se roconversion rate (34.8%vs 15.2%﹚, the HBsAg negative rate (28.3% vs 10.8%﹚, the ALT levels(51.6±12.4 vs 72.3± 15.3﹚U/L, the AST levels(51.8±12.8 vs 70.8±13.4﹚U/L, the TBiL levels(23.5±7.6 vs 33.4±6.8﹚μmol/L, the ALP lev-els(87.2±24.2 vs 158.4±28.7﹚U/L, the serum levels of total protein (76.2±9.2 vs 65.2±8.2﹚g/L, albumin (37.5±8.3 vs 32.3±7.9﹚g/L, and the A/G levels (1.8±0.3 vs 1.4±0.3﹚(P<0.05﹚. What’s more, during the course of treatment, the neutropenia rate(6.5%vs 26.1%﹚,thrombocytopenia incidence rate (4.3% vs 23.9%﹚also had significant difference be-tween the treatment group and control group (P<0.05﹚. Conclusion There is synergistic clinical efficacy of deoxynu-cleotide combined pegylated interferonα-2a, and less adverse events during treatment.